Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

7.370 -0.230 (-3.03%)
Streaming Delayed Price Updated: 2:59 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
QNTM CLASS ACTION DEADLINE: Kaplan Fox Reminds Investors of a Class Action Lawsuit Against Quantum Biopharma Ltd. (QNTM) and Lead Plaintiff Deadline on February 23, 2026
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
QNTM DEADLINE: Investors of Quantum Biopharma Ltd. (QNTM) are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 23, 2026
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Alerts Quantum Biopharma Ltd. (QNTM) Investors to a Securities Class Action Lawsuit - Deadline is February 23, 2026
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
QUANTUM BIOPHARMA Investors are Encouraged to Contact Kaplan Fox Regarding the Securities Class Action Lawsuit
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Reminds Quantum Biopharma Ltd. (QNTM) Investors of a Securities Class Action Lawsuit
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Encourages Investors of Quantum Biopharma Ltd. (QNTM) to Contact the Firm Regarding the Securities Class Action Lawsuit
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Alerts Investors of Quantum Biopharma Ltd. (QNTM) to a Securities Class Action Lawsuit
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) Shareholders
Via TheNewswire.com
Topics Law Enforcement Lawsuit
News headline image
Kaplan Fox Alerts Investors to Securities Class Action on Behalf of Quantum Biopharma Ltd. (QNTM) Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Law Enforcement Lawsuit
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Completes 180-Day Toxicity Studies for Lucid-MS
Via Investor Brand Network
News headline image
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)
Studies Will Support Investigational New Drug Application (IND) with the US FDA, Including Design of Phase 2 Trial 
From Quantum BioPharma
Via GlobeNewswire
News headline image
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
Via ACCESS Newswire
News headline image
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
From Quantum BioPharma
Via GlobeNewswire
News headline image
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlighted in CTV W5 Part 2 Covering Alleged Market Manipulation
Via Investor Brand Network
Topics Law Enforcement Lawsuit
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in CTV News W5 Series on Stock Manipulation Allegations
Via Investor Brand Network
Topics Lawsuit
News headline image
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC
From Quantum BioPharma
Via GlobeNewswire
News headline image
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
From Quantum BioPharma
Via GlobeNewswire
News headline image
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in CTV W5 Investigation on Alleged Stock Manipulation
Via Investor Brand Network
Topics Law Enforcement Lawsuit
News headline image
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
Quarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer 
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.